Company terminates existing sales agreement with BlueWave Healthcare Consultants
Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC) technology for clinical diagnostics and scientific discovery, today outlined a refinement of the Company’s commercial strategy which will expand its Clinical Lab Testing Services direct sales force throughout the United States.
In conjunction with this expansion, Singulex also announced the termination of its sales agreement with BlueWave Healthcare Consultants, Inc., an independent contract sales organization. “As more physicians recognize the clinical value of our SMCTM technology to measure important changes in biomarker levels, demand continues to grow for our SMCTM high value tests.
The nationwide expansion of our direct sales force will enable us to provide the best possible support to our growing customer base,” said Guido Baechler, President and Chief Executive Officer of Singulex. Previously, Singulex’s direct sales coverage was limited to those states in which it did not engage an independent contract sales organization.
By deploying additional sales representatives and leveraging its existing support infrastructure, the Company will expand its direct presence across an additional nineteen states in order to provide all its customers with high-quality service.
Follow Evolution Global Talent Attraction on Twitter, Facebook and LinkedIN to keep up-to-date with news and trends from the biotechnology, biosciences, medical device, IT and Intellectual Property industries.
